Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome
Status:
Terminated
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
Study TLK199.2107 is a multicenter, single arm, open-label Phase 2 study of oral ezatiostat
(Telintra®) in patients with lenalidomide (Revlimid®) refractory or resistant, red blood cell
(RBC) transfusion-dependent, Low to Intermediate-1 IPSS risk, del5q Myelodysplastic Syndrome
(MDS).